Building a medtech brand?
We run PR and public affairs for companies in this market: from category launches and funding announcements to NHS procurement and regulatory communications.
Ultromics
Cardiology AI (echocardiography)
Diagnostics & imaging
Oxford spinout building AI software that reads standard echocardiograms to flag hidden heart failure and cardiac amyloidosis, without any extra scanning equipment.
The read
Ultromics' EchoGo platform applies AI to standard echocardiogram videos to flag heart conditions that are easy to miss on manual reading, including heart failure with preserved ejection fraction and cardiac amyloidosis, using nothing more than a routine ultrasound clip. EchoGo Amyloidosis, developed with Janssen and support from Pfizer, was the first device to reach market authorisation through the FDA's Total Product Lifecycle Advisory Program.
Its $55m Series C in July 2025 brought in US health-system investors UChicago Medicine's venture arm and UPMC Enterprises alongside existing backers Oxford Science Enterprises and GV, reflecting a company now selling as much into US hospital cardiology departments as into the NHS.
The Bridgehead view
Ultromics' FDA Breakthrough Device route into cardiac amyloidosis, a condition notoriously under-diagnosed on conventional echo reads, is a sharper regulatory story than most diagnostics-AI pitches: a named clinical gap, a named pharma partner with a drug to sell into it, and a clearance pathway built for exactly that kind of urgency.
Recent coverage
- Ultromics Revenue 2025: $7.3M Est. ARR (Bootstrapped)GetLatka · 10 Aug 2026Ultromics 2025 estimated revenue: $7.3M ARR. 66 employees. Industry: Machine Learning Software. Founded 2017. HQ: United Kingdom Updated Aug 10, 2026.
- New AHA report highlights Ultromics’ AI tool’s benefit in earlier heart failure diagnosisMedical Device Network · 23 Jul 2026
- New AHA report highlights Ultromics’ AI tool’s benefit in earlier heart failure diagnosisMedical Device Network · 23 Jul 2026The AHA’s Impact Report was created using independent clinical and image data through its AI Assessment Lab.
FAQs
About this page
No. The MedTech Index is independent editorial coverage — we track and write up companies we judge genuinely significant in the sector, and inclusion is not for sale. Where shown, coverage of Ultromics above is drawn from public reporting, not sponsored content.
We map the sector by who is actually shaping it: funding, product reach, regulatory engagement and the coverage they earn. The MedTech Index is maintained by our editorial team and updated as the market moves, not compiled from vendor submissions.
Yes. If you represent Ultromics, or anything here looks out of date, get in touch through our contact page and we will review it.
Work with us
Working across the healthcare sector?
We advise NHS-facing organisations, providers and health systems on reputation, policy engagement and communications that understand the sector.
Related platforms
Others in the sector map
Stroke and lung imaging AI
Brainomix
Oxford University spinout building AI imaging biomarkers for stroke and lung disease, used to speed emergency treatment decisions from CT and MRI scans.
ReadAI pathology platform
Panakeia
Cambridge AI pathology company whose software reads standard tumour tissue slides to deliver molecular cancer profiling in minutes rather than the weeks conventional genomic testing takes.
ReadBreath biopsy diagnostics
Owlstone Medical
Cambridge diagnostics company building breath-based tests, its Breath Biopsy platform, to detect cancer and other diseases from volatile organic compounds on a patient's breath.
ReadAI cancer pathology and genomics platform
Sonrai Analytics
Belfast-founded, Queen's University spinout building an AI platform that reads cancer biopsy slides and multi-omic data to support faster, more consistent pathology diagnosis.
ReadRare disease diagnosis AI
Mendelian
AI clinical decision support that scans GP electronic health records to flag patients who may have one of thousands of rare diseases, years earlier than standard care typically catches them.
ReadSelf-test IVD manufacturer
BioSure
Essex-based manufacturer of CE-marked self-test IVDs, best known for producing the world's first CE-marked HIV self-test, sold through UK pharmacies and the NHS.
ReadThe firm that knows medtech
We map this sector because
we represent it.
Whether you build medical technology or run the health systems that buy it, we know the market, the media and the regulatory landscape it operates in. Thirty minutes with a partner tells you if we can help.
